The TOBI PODHALER delivery system uses the PULMOSPHERE Technology, delivering up to 60% of active drug1
  • Tobramycin inhalation powder is delivered to both the central and peripheral airways1
  • Low interparticle cohesive forces and smaller particle size allow for the necessary dispersibility during inhalation1
  • TOBI PODHALER is the first and only FDA-approved dry powder inhaled antibiotic for Pseudomonas aeruginosa — no nebulizer required
Characteristics of PULMOSPHERE powder particles1
  • Low in density
  • Light and porous hollow particle
  • Particle size: median geometric diameter is 1.7-2.7 µm
  • Minimal effort is required to disperse the particles*
  • Low particle-to-particle cohesion supporting dispersibility
  • Lung deposition to both central and peripheral airways
  • PULMOSPHERE Technology enables rapid drug release using a device that requires little additional energy1

Watch a video on PULMOSPHERE Technology

 

*The lung deposition fraction of PULMOSPHERE particles was evaluated in healthy volunteers by using gamma scintigraphic images.1

REFERENCE

  1. Geller DE, Weers J, Heuerding S. Development of an inhaled dry-powder formulation of tobramycin using PULMOSPHERE® Technology. J Aerosol Med Pulm Drug Deliv. 2011;24(4):175-182. doi:10.1089/jamp.2010.0855.